EXHIBIT 99.1

[VENTIV LOGO]

Contacts:
Investors/Corporate:                                 Media:
John R. Emery                                        Lynn Blenkhorn
Chief Financial Officer                              Noonan/Russo Communications
(732) 537-4800                                       (212) 696-4455
investor@ventiv.com                                  Media@ventiv.com
-------------------                                  -----------------



 VENTIV HEALTH, INC. ANNOUNCES CONVERSION OF RELIANT PHARMACEUTICALS SALES FORCE

NEW YORK, February 5, 2002 -- Ventiv Health, Inc. (Nasdaq:VTIV), a leading
provider of comprehensive marketing and sales solutions to the pharmaceutical
and life sciences industries, announced today it has been notified by Reliant
Pharmaceuticals, LLC, of Reliant's intent to convert the field sales force
working under the Ventiv-Reliant contract from full-time Ventiv employment to
full-time Reliant employment effective April 1, 2002. The Ventiv-Reliant
contract, which commenced on August 1, 2000, provided Reliant with the option to
convert all or a portion of the field sales force to Reliant employment at any
time. Ventiv will work with Reliant to ensure the conversion is implemented
smoothly.

Mr. Eran Broshy, President and CEO of Ventiv, said "As with many of our
contracts, we have always known that conversion of the Reliant sales force was a
possibility. We are pleased we were able to help Reliant develop its
commercialization infrastructure during the past 18 months."

Mr. Joseph Krivulka, President of Reliant Pharmaceuticals, stated "The level of
service provided by Ventiv during the past 18 months helped us to reach this
important milestone in Reliant's history. We appreciate Ventiv's contribution to
our company's current and future success."

On February 28, 2002, Ventiv plans to announce its results for the quarter and
year ended December 31, 2001. At that time, Ventiv will also provide guidance on
its financial outlook for the remainder of 2002, which will incorporate the
termination of the Reliant contract, as well as other current and anticipated
developments.

This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks that may cause Ventiv Health's
performance to differ materially. Such risks include, without limitation:
changes in trends in the pharmaceutical industry or in pharmaceutical
outsourcing; our ability to compete successfully with other services in the
market; our ability to maintain large client contracts or to enter into new
contracts; uncertainties related to future incentive payments and revenue share
agreements; and, our ability to operate successfully in new lines of business.
Readers of this press release are referred to documents filed from time to time
by Ventiv Health, Inc. with the Securities and Exchange Commission for further
discussion of these and other factors.